Anti-angiogenic peptides and methods of use thereof

Details Anti-angiogenic peptides and methods of use thereof Anti-angiogenic peptides and methods of use thereof

2005-02-08

2005-02-08

Helms, Larry R. (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S501000, C530S350000

Reexamination Certificate

active

06852691

ABSTRACT:
EM 1, a novel anti-angiogenic protein, and a deletion mutant of endostatin, is described, as well as methods of making EM1, therapeutic compositions comprising EM1, and methods for using those compositions.

REFERENCES:
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 6080728 (2000-06-01), Mixson
patent: WO 9715666 (1997-05-01), None
patent: WO 9929855 (1999-06-01), None
patent: WO 9929856 (1999-06-01), None
patent: WO 9929878 (1999-06-01), None
patent: WO 0017240 (2000-03-01), None
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.*
Lazar et al. Molecular and Cellular Biology 8:1247-1252, 1988.*
Bowie et al. Science, 247:1306-1310, 1990.*
Oh, et al., 1994, Proc. Natl. Acad. Sci., USA, vol. 91, pp. 4229-4233.*
O'Reilly, et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth”,Cell88:277-285 (1997).
Ständker et al., “Isolation and Characterization of the Circulating Form of Human Endostatin”,FEBS:129-133 (1997).
Dhanabal, et al., Endostatin: Yeast Production, Mutants, and Antitumor Effect in Renal Cell Carcinoma,Cancer Research,59;189-197 (1999).
Hohenester, et al., “Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution”,EMBO Journal:17(6):1656-1664 (1998).
Nguyen, et al., “Genetic Strategies for Anti-Angiogenic Therapy of Solid Tumors”, p. 1 (1997).
Boehm, et al., “Zinc-Binding of Endostatin is Essential for Its Antiangiogenic Activity”,Biochemical and Biophysical Research Communication, 252:190-194 (1998).
Ding et al., “Zinc-Dependent Dimers Observed in Crystals of Human Endostatin”,Proc. Natl. Acad. Sci.,95:10443-10448 (1998).
Folkman, J., “Endogenous Inhibitors of Angiogenesis”,The Harvey Lectures, Series 92:65-82 (1998).
Dhanabal, et al., “Cloning, Expression, and In Vitro Activity of Human Endostatin”,Biochemical and Biophysical Research Communications, 258:345-352 (1999).
Bachelot, T. et al., “Retrovirus-medicated gene transfer of an Angiostatin-Endostatin fusion protein with enhanced anti-tumor properties in vivo”,Proceedings of the 89thAnnual Meeting of the American Association for Cancer Research39:271 (Mar. 1998).

Affiliated with

Also associated with

Rating

Anti-angiogenic peptides and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-angiogenic peptides and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-angiogenic peptides and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3476652